foxo4-dri peptide senolytic skin for Research Use foxo4 dri senolytic mice baar

Cutting-edge peptides backed by clinical research formulated for therapeutic efficacy

The peptide retains activity in human gastric juice for more than 24 hours, tolerates pH from 1 to 11, and resists multiple proteolytic enzymes, properties that derive from the high proline content (four of fifteen residues) and the absence of cleavage-prone motifs

Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program

Most patients begin to notice weight loss during the first month

Nitric oxide (NO) modulation